

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12P 13/00, 9/00 C07C 229/00	A1	(11) International Publication Number: WO 91/16444 (43) International Publication Date: 31 October 1991 (31.10.91)
(21) International Application Number: PCT/US91/02608 (22) International Filing Date: 16 April 1991 (16.04.91) (30) Priority data: 513,285 17 April 1990 (17.04.90) US (71) Applicant: THE LIPOSOME COMPANY, INC. [US/US]; One Research Way, Princeton-Forrestal Center, Princeton, NJ 08540 (US). (72) Inventors: TREMBLAY, Paul, A. ; 2633 Nottingham Way, Hamilton, NJ 08619 (US). MARZIANI, Frank ; 1717 Crestview Avenue, Willow Grove, PA 19090 (US). TINO, John, A., F. ; 15 Danbury Drive, Cranbury, NJ 08512 (US). PILKIEWICZ, Frank, G. ; 3 Davenport Drive, Cranbury, NJ 08512 (US).		(74) Agent: BLOOM, Allen; The Liposome Company, Inc., One Research Way, Princeton-Forrestal Center, Princeton, NJ 08540 (US). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), HU, IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent). Published <i>With international search report.</i>
(54) Title: ENZYMATIC SYNTHESIS OF SOLUBLE PHOSPHATIDES FROM PHOSPHOLIPIDS (57) Abstract A method of preparing a soluble monovalent salt of a phosphatidyl ester which comprises reacting a phospholipid with a primary alcohol in the presence of an enzyme catalyst in a divalent cationic buffered solution and a water immiscible non-ether solvent that does not inactivate the enzyme, to form a divalent cationic salt of the phosphatidyl ester, and suspending the product in the presence of a stoichiometric amount of a monovalent cationic salt whose anion forms an insoluble salt with the divalent cation. The use of Centrifugal Partition Chromatography facilitates the enzyme reaction. The monovalent salt is preferably an ammonium/sodium mixed salt.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

ENZYMATIC SYNTHESIS OF SOLUBLE PHOSPHATIDES
FROM PHOSPHOLIPIDS

CORRESPONDING U.S. PATENT APPLICATIONS

This application is a continuation-in-part of copending U.S. application Serial No. 513,285 filed April 17, 1990.

BACKGROUND OF THE INVENTION

This invention relates to an improved synthesis of soluble phosphatides from phospholipids using phospholipase D enzyme as a catalyst, whereby high yields of high purity soluble phosphatides are obtained.

Phosphatides such as phosphatidyl glycerol are valuable and useful products used for making liposomes and lipid complexes.

Phosphatidyl glycerols and other phosphatides have been made heretofore by mixing an aqueous buffer solution containing calcium acetate, acetic acid and an enzyme, phospholipase D, and glycerol or other primary alcohol, with a phosphatidyl lipid, such as phosphatidyl choline, dissolved in a water immiscible organic solvent. In order to activate the enzyme, either a solvent such as ether has been used, or a surfactant has been added to emulsify the mixture of water insoluble and aqueous solutions.

Dimethyl ether, diethyl ether and other ethers, as has been disclosed by Redemann, PCT Application No. WO 89/01524 published February 23, 1989, have been used to activate the enzyme, but these are known to be hazardous because of their flammability and their peroxide forming properties, which promote the auto-oxidation of the

phosphatides. In addition, because of the very low density of ethers as compared to water, good mixing of the mixture of phases requires vigorous shaking, which can be difficult to scale up to commercial quantities.

Surfactants are useful also to activate the enzyme, but they are difficult to remove from the desired product. Thus, elaborate and expensive column chromatography separations are required to obtain a phosphatide of useful purity. Further, the presence of water in relatively large amounts results in hydrolysis and the concurrent production of phosphatidyl acid, which reduces the yield of the desired phosphatide product, and which also must be separated from the desired phosphatide.

Further, the enzyme requires an optimum pH range which necessitates the use of buffer solutions. The enzyme also requires a divalent cation such as calcium ion in the reaction mixture which produces the phosphatide as the calcium or other divalent cationic salt, which precipitates out of solution and therefore is difficult to solubilize. If acidification or ion exchange resin and neutralization are used to convert the calcium salts to their more soluble monovalent salts, very rapid hydrolysis occurs, with the concomitant precipitation of products of decomposition such as lysophosphatidyl glycerol or phosphatidyl acid, with the problems enumerated above.

In an attempt to improve the yields of phosphatides such as phosphatidyl glycerol, a process whereby a phosphatidyl lipid is reacted in an organic solvent with phospholipase D fixed on a carrier having hydrophobic groups has been disclosed. The solvent can be diethyl ether or an alkane which can dissolve phosphatidyl lipids such as phosphatidyl choline. The reaction is carried out at a temperature below the boiling point of the organic solvent, such as 15 to 35°C. However, yields of the desired phosphatide are low, on the order of 45%, and use of the ether solvents is inconvenient because they are highly flammable and dangerous solvents.

Thus, a method to produce phosphatides in a safe, simple manner in improved yield and in the form of a water soluble, monovalent, stable salt, has long been sought.

Previously, this transesterification reaction was usually done in a two phase system with ether in order to activate the reaction to a useful rate. However, the reaction was seldom quantitative as significant quantities of phosphatidic acid were also generated. In addition, due to the large difference in densities between the ether and the aqueous phase, large scale reactions gave limited yields due to insufficient mixing. Detergents may be used, but resulted in an increased difficulty in purifying the product.

SUMMARY OF THE INVENTION

In accordance with the invention, a phospholipid such as phosphatidyl choline can be reacted with a primary alcohol in the presence of (i) an enzyme catalyst such as phospholipase D, (ii) a non-ether solvent that is non-destructive and non-denaturing to the enzyme and less flammable than ethers, and (iii) a buffered divalent salt solution, preferably the calcium salt, to form the corresponding phosphatidyl ester as a divalent salt. The insoluble divalent salt is converted to an organic soluble, stable monovalent salt by suspending the divalent salt in an organic solvent, and adding a stoichiometric amount of a solid monovalent salt which simultaneously solubilizes the phosphatide and precipitates the calcium salt of the anion of the added monovalent cation salt. This procedure produces the monovalent salt of the phosphatide without substantial formation of hydrolysis products such as phosphatidyl acid.

It has also been found that for a particular ester salt, dimyristoylphosphatidyl glycerol mixed ammonium/sodium salt, when the ratio of ammonium to sodium ions is a particular ratio by weight, and the amount of the divalent cation present is limited, the solubility and stability of the dimyristoylphosphatidyl glycerol

salt is maximized. In order to maximize the stability and solubility of a mixed ammonium/sodium salt of dimyristoylphosphatidyl glycerol in an organic solvent, it has been found that the percent by weight of ammonium ion should be between about 2.0 and about 2.6 percent by weight of the mixed salt, and the percent by weight of sodium ion should be between about 0.3 and about 0.8 percent by weight of the mixed salt. The maximum calcium level should be about 0.1, preferably about 0.05 percent by weight of the mixed salt.

Further, it has been found that Centrifugal Partition Chromatography (CPC) may be used to greatly facilitate the enzyme reaction of phospholipase D with phosphatidyl choline and glycerol or some other alcohol.

BRIEF DESCRIPTION OF THE DRAWING

FIG. 1 is a graph of solubility versus ammonium ion content in methylene chloride for dimyristoylphosphatidyl glycerol mixed salt.

DETAILED DESCRIPTION OF THE INVENTION

The present process is a two step process for forming a monovalent salt of a phosphatidyl ester which comprises:

a) reacting a phospholipid with a primary alcohol in the presence of a suitable enzyme catalyst, such as phospholipase D, and a divalent cationic buffer solution in an aqueous-immiscible solvent having low flammability to form the corresponding insoluble phosphatide of the divalent cationic salt, and

b) converting the divalent cationic salt of the phosphatide to its corresponding soluble monovalent salt by suspending it with a stoichiometric amount of a solid monovalent salt whose anion forms an insoluble precipitate with the divalent cation.

Due to their improved solubility and stability, the compounds of this invention, are particularly useful in liposome and lipid complex compositions.

Liposomes are completely closed lipid bilayer membranes containing an entrapped aqueous volume. Liposomes may be unilamellar vesicles (possessing a single bilayer membrane) or multilamellar vesicles (onion-like structures characterized by multiple membrane bilayers, each separated from the next by an aqueous layer). The bilayer is composed of two lipid monolayers having a hydrophobic "tail" region and a hydrophilic "head" region. The structure of the membrane bilayer is such that the hydrophobic (nonpolar) "tails" of the lipid monolayers orient toward the center of the bilayer while the hydrophilic "head" orient towards the aqueous phase.

Liposomes comprising dimyristoylphosphatidyl choline (DMPC), dimyristoylphosphatidyl glycerol (DMPG) and cholesterol encapsulating amphotericin B, are useful in the treatment of systemic fungal infections. Juliano et al., *Annals N.Y. Acad. Sci.*, 1985, 446:390-402; Lopez-Berenstein et al., *J. Infect. Dis.*, 1986, 151:704-710.

PCT Publication No. WO88/06443, entitled "Low Toxicity Drug-Lipid Systems", Janoff et al., published on September 7, 1988, describes methods of making of high drug:lipid complexes of drug-associated lipids in particulate non-liposomal form, or HDLC's, and liposomes containing a specific ratio of DMPC and DMPG. The phospholipids are solubilized in solvents such as chloroform and methylene chloride.

HDLC's are prepared by first solubilizing a drug, particularly where the drug is a polyethylene antifungal antibiotic such as amphotericin B, in a biocompatible organic solvent, such as dimethylsulfoxide (DMSO) or methanol, and mixing the resultant solution with lipid(s), such as DMPC:DMPG in a 7:3 mole ratio, which have been solubilized in a solvent such as methylene chloride. The solvents are evaporated under reduced pressure, resulting in a thin lipid-drug film. The film is hydrated in an aqueous solution such as saline, PBS, or glycine buffer, forming HDLC's. Alternatively, the aqueous solution may be added to the solvent-containing drug and

lipid phase prior to evaporation of the solvent. As an alternative, the resulting dry lipid-drug film may be resuspended in a solvent, such as methylene chloride and again evaporated under reduced pressure prior to hydrating the film. A dehydration procedure may also be used wherein a dry lipid-drug film is dehydrated to form a flake which is hydrated with aqueous solution. In an alternative method for forming HDLC's, lipid particles containing bioactive agent made by the MLV process are formed and then the particles are subjected to a heating cycle, at about 25°C to about 60°C.

The phospholipids useful in the present invention are a class of natural and synthetic lipids which contain one or more phosphatidyl groups. They include phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidic acid, dimyristoylphosphatidyl choline and phosphatidyl inositol. Phosphatidyl choline is readily available commercially in high purity and is thus preferred.

The primary alcohol illustrated herein is glycerol, but other primary alcohols such as sulfocholine, ethylene glycol, glycidol, ribose, ethanolamine, glycerolformal and the like can be used. Simple primary alcohols such as methanol, ethanol, propanol and the like must be carefully excluded as they react extremely rapidly to form the corresponding alkyl ester.

Suitable divalent cationic buffers have a pH of about 5.7 and contain a divalent cation such as calcium. The cation should be inactive with respect to the enzyme. For example, the buffer can be a solution of one or more of the following: calcium hydroxide, calcium chloride or calcium acetate with acetic acid or sodium acetate, as an example.

The non-flammable, or low flammable, water immiscible solvent useful in the invention is one that is less flammable than diethyl ether or dimethyl ether; has a flash point of over 0°C, and preferably over 20°C; and one that will not degrade or denature the enzyme so as to reduce its activity more than about 25% below that

of diethyl ether. Suitable solvents for the present process include halogenated solvents such as methylene chloride, chloroform, tetrachloroethylene, trichlorofluoromethane and the like. Aliphatic or aromatic esters, alkanes, ketones or esters having a molecular weight below about 5000 can also be used, such as ethyl acetate, ethyl propionate, ethyl butyrate, methyl acetate, methyl propionate, 3-pentanone, 3-heptanone, 2-octanone, 2-butanone, 2-pentanone, 2-heptanone, 3-octanone and 4-heptanone and the like.

The above reactants are mixed together, as by stirring or shaking to convert the initial phosphatidyl ester, such as phosphatidyl choline, to the divalent cationic salt of the desired product, such as the calcium salt of phosphatidyl glycerol, for example.

Generally low energy mixing such as stirring or vortexing, will be sufficient to obtain at least about 80% of the projected yield of the divalent cationic salt.

Centrifugal Partition Chromatography (CPC), Cazes, J. "High Performance CPC for Downstream Processing of Biomaterials", American Biological Laboratories, June 1989, 17-23, may be used to facilitate the transesterification reaction of the enzyme with the phospholipid and the alcohol. A stationary aqueous phase, consisting of a suitable buffer of about 5.6, such as sodium acetate, is loaded with calcium chloride, a suitable alcohol and the enzyme into the centrifuge. The centrifuge is set into motion and a mobile phase, consisting of an organic nonalcoholic solvent such as ethyl acetate or ethyl butyrate, containing the phospholipid is pumped into the CPC system. The calcium salt of the saturated phosphatidyl glycerol, such as DMPG, precipitates from the eluant. The unreacted soluble phosphatidyl choline is then recirculated to increase the yield. The phosphatidyl glycerol (DMPG) may then be further purified. One skilled in the art would understand conditions to employ for this.

The temperature at which the reaction is run is generally between about 15°C and 50°C, preferably between about 20 and 37°C, and most preferably about 20 to 30°C.

The divalent cationic salt precipitates and can be readily separated from the enzyme and other by-products of the reaction by filtration, and washing with a water-immiscible organic solvent, such as ethyl acetate followed by methylene chloride, to further purify it.

The divalent cationic salt is converted in the presence of an organic solvent phase, such as methyl alcohol and chloroform, to a soluble monovalent salt by reacting in suspension with about a stoichiometric amount of a monovalent salt whose anion forms a precipitate with the divalent cation. The preferred monovalent cations are ammonium, sodium and potassium as their carbonates, citrates, fluorides, sulfates, phosphates, nitrates, lactates, succinates, formates, oxalates, chlorides ethylene diamine tetraacetates, ethylene bis (oxyethylene nitrilo) tetraacetates and the like, all of which have significant water solubility. The phosphatidyl monovalent salts remain in solution and the divalent salt precipitates and can be readily removed by filtration and the like. At least 25% conversion, and generally a 35% conversion or higher, is readily obtained. Because of the volatility of ammonia in ammonium salts, which are desirable because of their high solubility, it is preferred to prepare a mixed ammonium/sodium salt for good solubility and good stability. A preferred molar ion ratio of ammonium to sodium is about 1:1 to about 8:1. A particularly preferred ion ratio of ammonium to sodium is a 4:1 molar ratio.

The ammonium salt of dimyristoylphosphatidyl glycerol is quite soluble in organic solvents such as methylene chloride. The solubility of the ammonium salt of dimyristoylphosphatidyl glycerol in methylene chloride is greater than about 26 mg/ml. However, this salt tends to be unstable. The sodium salt is more stable, but much less soluble; for example, the solubility of sodium salt of dimyristoylphosphatidyl glycerol in methylene chloride is less than

about 0.2 mg/ml. Particular proportions of the sodium salt with the ammonium salt will stabilize the mixed salt, but without adversely affecting the solubility below satisfactory levels when the amount of sodium salt is controlled. About 0.3% by weight of the sodium cation confers stability; however, above a maximum amount of about 0.8% by weight of sodium, the solubility of the mixed salt in methylene chloride is decreased.

The amount of residual calcium ion should be limited to below about 0.1, preferably about 0.05 percent by weight of the mixed salt. The calcium salt is insoluble and the presence of excess calcium ion has an adverse effect on the solubility of the mixed salt in relatively non-polar organic solvents.

It is to be noted however that even when the mixed ammonium/sodium salt of dimyristoylphosphatidyl glycerol has a calcium ion content of more than about 0.1 percent or about 0.05 percent by weight and a sodium ion content of more than about 0.8 percent by weight, the solubility of the salt increases markedly when the ammonium ion content is above about 2.0 percent by weight and is very high when the ammonium ion content is about 2.25 to about 2.35 percent by weight (Figure 1 and Table II).

Generally if the calcium ion content is above about 0.05 percent by weight or if the ammonium ion levels are less than about 2.0 percent by weight, the percent of insolubles of mixed ammonium/sodium salts of dimyristoylphosphatidyl glycerol in methylene chloride increases (see Table III).

Thus, also in accordance with the process of the present invention, after precipitating the calcium salt of dimyristoylphosphatidyl glycerol, washing and filtering, both ammonium carbonate and sodium carbonate is added in an amount to convert the calcium anion to a solid calcium salt, i.e., the carbonate. Preferably monovalent carbonates are not added in excess

of the stoichiometric amount needed to precipitate the calcium and as the calcium carbonate salt. The ammonium/sodium mixed salt of dimyristoylphosphatidyl glycerol is separated from the insoluble calcium salt and can be further purified if desired.

If further purification is desired, chromatographic purification using an ammoniacal silica column can be employed with mixed methanol/chloroform solvents in a known manner.

The process of the invention is carried out in the absence of detergents or other surfactants that generally must later be removed; and it produces a high purity product in high yield, without the concomitant production of phosphatidyl acid or other by-products that reduce the yield of the desired phosphate ester salts, and require purification to remove.

The process of the invention will be further described with reference to the following examples, but the invention is not meant to be limited to the details described therein. All reactions were carried out at about 23°C.

EXAMPLE 1

200 Mg of phosphatidyl choline was emulsified in a solution of 1 ml of sodium acetate buffer having a pH of 5.6, 1 ml of water, 0.2 ml of 1M calcium chloride and 0.2 ml of glycerol.

One mg of phospholipase D in 1 ml of sodium acetate and 1 ml of water were added to the above emulsion and 2 ml of methylene chloride were added and the mixture stirred for 17 hours.

The phosphatidyl glycerol precipitate was filtered, washed with 10 ml of methylene chloride and recovered as the calcium salt in 74% yield.

140 Mg of the calcium salt as obtained above was suspended in 6 ml of ethanol and 3 ml of hexane and a stoichiometric amount of a 1:4 molar mixture of sodium carbonate/ammonium carbonate was added and stirred.

The precipitate of calcium carbonate was removed by filtration. A yield of 120 mg or 78% of sodium/ammonium phosphatidyl glycerol was obtained.

EXAMPLE 2

100 Grams of dimyristoylphosphatidyl choline were charged to a 5 liter container, 500 ml of water and 500 ml of 0.5N sodium acetate buffer having a pH of 5.6 were added, and 100 ml of M calcium chloride and 100 mg of phospholipase D dissolved in 50 ml of the buffer and 50 ml of water. One liter of ethyl butyrate was added, the container sealed and shaken for 17 hours.

Calcium dimyristoylphosphatidyl glycerol was recovered as a precipitate. The product was filtered on a Buchner funnel, washed with 5 liters of ethyl acetate and given a final 1 liter wash with methylene chloride.

The filter cake was suspended in 1052 ml of methanol, 526 ml of chloroform and 420 ml of water.

526 Ml of 1:1 by volume of 2N ammonium carbonate and 0.5 N sodium carbonate was added. The mixture was quickly filtered and 526 ml of chloroform added to the filtrate. The chloroform was evaporated to about 200 ml and 5 liters of cold acetone were added.

The mixture was filtered through a Buchner funnel, and the recovered DMPG washed with cold acetone.

95 Grams (95% yield) of sodium/ammonium dimyristoylphosphatidyl glycerol was obtained.

The above product was purified further by dissolving in 20% methanol in chloroform, loaded onto a 1 inch silica column and eluted with a mixed solvent of 80% chloroform/20% methanol containing 1% of ammonium hydroxide.

The fraction containing the dimyristoylphosphatidyl glycerol product was separated and evaporated to dryness. Dimyristoylphosphatidyl glycerol mixed ammonium/sodium salt of 99% purity was obtained.

EXAMPLE 3

200 Grams (0.29 mol) of dimyristoylphosphatidyl choline was charged to a five liter three necked flask equipped with a banana paddle to which 1 liter of 0.5N sodium acetate buffer having a pH of 5.6, 1 liter of water, 200 ml of glycerol and 200 ml of M calcium chloride were added. The pH was adjusted to 5.5.

80 Milligrams of phospholipase D dissolved in 5 ml of sodium acetate buffer and 5 ml of water was added to the flask. Finally, 1 liter of methylene chloride was added to the mixture stirred for 17 hours.

The reaction mixture was filtered on a Buchner funnel and the filter cake washed with 5 liters of water and 5 liters of methylene chloride.

166 Grams (0.24 mol) of calcium dimyristoylphosphatidyl glycerol or a yield of 82% was obtained. The product was determined to be 95% pure by thin layer chromatography.

EXAMPLE 4

A series of sample tubes were each charged with a suspension consisting of 200 milligrams of dimyristoylphosphatidyl choline; 2 ml of 0.25 M sodium acetate buffer having a pH of 5.6; 200 ml of molar calcium chloride; 200 ml of glycerol and 5 milligrams of phospholipase D in 2 ml of 0.25 M sodium acetate buffer having a pH of 5.6

2.5 ml each of various solvents (see Table I) was added to each tube. The tubes were capped and placed on a shaker at 25°C. The shaker was set at 250 rpm and run for 17 hours. The shaker was stopped and each tube was examined and the contents washed 3 times with 5 ml of chloroform, and then with 5 ml of acetone, and dried in vacuo to a constant weight. A sample of each was analyzed by thin layer chromatography (TLC) on silica gel with chloroform:methanol:ammonia in the volume ratio of 65:35:5. The results are given in Table I below:

TABLE I

<u>Solvent</u>	<u>Yield of Insoluble</u> <u>Product mg**</u>
----------------	--------------------------------------------------

ethyl acetate	183
ethyl propionate	205*
ethyl butyrate	254*
2-butanone	78
2-pentanone	78
2-heptanone	162
2-octanone	166
butyl acetate	126
3-pentanone	150
3-heptanone	116
3-octanone	9
4-heptanone	175
carbon tetrachloride	5
chloroform	46
methylene chloride	185
ether	190

*High values probably due to nonhomogeneous liposome suspension

**TLC showed conversion of phosphatidyl choline to calcium salt of phosphatidyl glycerol with the unreacted phosphatidyl choline being washed away.

EXAMPLES 5-10

The solubility in methylene chloride of various mixed ammonium/sodium salts of dimyristoylphosphatidyl glycerol was determined. 1.6 Mg of each mixed salt was mixed and heated at 35°C while stirring, for one and two hours. The mixture was filtered through a 0.2 micron 25 mm syringe filter (Gelman Acrodisc CR) and percent solubility was determined. The results are summarized below in Table II.

TABLE II

<u>Example</u>	<u>%NH₄</u>	<u>%Na⁺</u>	<u>%Ca²⁺</u>	<u>Percent Solubility</u>	
				<u>1 Hour</u>	<u>2 Hours</u>
5	2.28	0.34	0.19	94	98
6	1.64	1.11	0.06	62	64
7	1.59	1.08	0.09	60	65
8	1.97	0.75	0.05	76	83
9	2.32	0.55	0.33	-	92
10	2.11	0.51	0.26	-	79

Figure 1 is a graph of solubility versus ammonium ion content in methylene chloride. The graph shows that even when the calcium exceeds about 0.05% by weight and the sodium content exceeds about 0.8% by weight, the solubility increases markedly when the ammonium ion content is above about 2.0 percent, and is very high when the ammonium ion content is about 2.25 to about 2.35 percent.

Example 11

0.2 M sodium acetate buffer pH 5.6, is loaded with 0.3 M calcium chloride, 0.3 M glycerol and phospholipase D into a Centrifugal Partition Chromatography (CPC) system. The centrifuge is set in motion and ethyl acetate or ethyl butyrate containing 0-20 % phosphatidyl choline is pumped into the CPC system. The calcium salt of DMPG precipitates from the eluant and may be further purified. The unreacted soluble phosphatidyl choline's may be recirculated.

COMPARATIVE EXAMPLES 1-4

The solubility in methylene chloride of various mixed ammonium/sodium salts of dimyristoylphosphatidyl glycerol was determined. 1.6 Mg of each mixed salt was combined with 4.5 mg of dimyristoylphosphatidyl choline and mixed and heated at 35°C for one hour. The material was then passed through a 0.2 micron 25 mm syringe filter (Gelman Acrodisc CR) and the percent of insolubles was calculated. The results are summarized below in Table III.

TABLE III

<u>Example</u>	<u>Percent by weight</u>			<u>Solubles</u>	<u>Percent</u>
	<u>Na⁺</u>	<u>NH₄⁺</u>	<u>Ca²⁺</u>	<u>%</u>	<u>Insolubles</u>
C1	0.38	2.26	0.2	95	5
C2	0.51	2.11	0.26	89	11
C3	1.11	1.64	0.06	91	9
C4	0.75	1.97	0.05	95	5

COMPARATIVE EXAMPLE 5

A batch of 1.6 mg/ml of mixed ammonium/sodium dimyristoylphosphatidyl glycerol having a sodium content of 1.20%, ammonium content of 1.53% and calcium content of 0.12% by weight of the salt, was admixed with 4.5 mg/ml of dimyristoylphosphatidyl choline in methylene chloride, and heated at 35°C while stirring. The mixture was still cloudy after one hour, indicating incomplete solubilization of the mixed salt.

WHAT IS CLAIMED IS:

1. A process for forming a soluble monovalent salt of a phosphatidyl ester which comprises:
 - a) reacting a phospholipid with a primary alcohol in the presence of (i) an enzyme catalyst,
 - (ii) a divalent cationic buffer solution, and
 - (iii) a water immiscible non-ether solvent, so as to form the corresponding phosphatide of the divalent cationic salt; and
 - b) converting the divalent cationic salt to an organic soluble monovalent salt by suspending with a stoichiometric amount of a monovalent salt whose anion forms an insoluble precipitate with the divalent cation.
2. The process according to claim 1 wherein the phospholipid is phosphatidyl choline.
3. The process according to claim 1 wherein the phospholipid is dimyristoylphosphatidyl choline.
4. The process according to claim 1 wherein the alcohol is selected from the group consisting of glycerol, sulfocholine, ethylene glycol, glycidol, ribose, ethanolamine and glycerolformal.
5. The process according to claim 4 wherein the alcohol is glycerol.
6. The process according to claim 1 wherein the buffer solution contains a calcium salt.

7. The process according to claim 1 wherein the water immiscible solvent is a halogenated alkane or alkene selected from the group consisting of methylene chloride, chloroform, tetrachloroethylene and trichlorofluoromethane.
8. The process according to claim 1 wherein the water immiscible solvent is an aliphatic or aromatic ester, alkane, ketone.
9. The process according to claim 8 wherein the water immiscible solvent is a member of the group consisting of ethyl acetate, ethyl propionate, ethyl butyrate, methyl acetate, methyl propionate, 2-butanone, 2-pentanone, 2-heptanone, 2-octanone, 3-pentanone, 3-heptanone, 3-octanone and 4-heptanone.
10. The process according to claim 1 wherein the monovalent cation of the monovalent salt is selected from one or more of the group consisting of ammonium, sodium and potassium.
11. The process according to claim 10 wherein the anion of the salt is a carbonate, citrate, sulfate, phosphate, nitrate, lactate, succinate, formate, oxalate, ethylene tetraacetate, ethylene bis(oxyethylene nitrilo)tetraacetate, or chloride.
12. The process according to claim 1 wherein step a) is carried out using Centrifugal Partition Chromatography.
13. A liposome comprising a soluble monovalent salt of a phosphatidyl ester formed according to claim 1.
14. A lipid complex comprising a soluble monovalent salt of a phosphatidyl ester formed according to claim 1.

15. A process for forming a soluble mixed ammonium/sodium salt of dimyristoylphosphatidyl glycerol which comprises:

a) reacting a dimyristoylphospholipid with a primary alcohol in the presence of (i) an enzyme catalyst,

(ii) a divalent cationic buffer solution, and

(iii) an aqueous-immiscible non-ether solvent, so as to form the corresponding phosphatide of the divalent cationic salt; and

b) converting the divalent cationic salt to an organic soluble monovalent salt by suspending with a stoichiometric amount of a monovalent salt whose anion forms a precipitate with the divalent cation and whose cation is a mixture of ammonium and sodium in a weight ratio so as to form a mixed monovalent dimyristoylphosphatidyl glycerol containing from about 2.0 to 2.6% by weight of ammonium and from about 0.3 to 0.8% by weight of sodium.

16. The process according to claim 15 wherein the divalent cation is calcium.

17. The process according to claim 15 wherein the mixed monovalent dimyristoylphosphatidyl glycerol contains not more than about 0.1% by weight of the mixed salt of calcium.

18. The process according to claim 17 wherein the mixed monovalent dimyristoylphosphatidyl glycerol contains not more than about 0.05% by weight of the mixed salt of calcium.

19. The process according to claim 15 wherein step a is carried out using Centrifugal Partition Chromatography.

20. A liposome comprising a soluble monovalent salt of dimyristoylphosphatidyl glycerol formed according to claim 15.

21. A lipid complex comprising a soluble monovalent salt of dimyristoylphosphatidyl glycerol formed according to claim 15.

22. An aqueous solution of mixed salt of dimyristoylphosphatidyl glycerol comprising from about 2.0 to about 2.6% by weight of ammonium, from about 0.3 to about 0.8% by weight of sodium.

23. The solution according to claim 22 wherein the mixed monovalent salt of dimyristoylphosphatidyl contains not more than about 0.1% by weight of the mixed salt of calcium.

24. The solution according to claim 23 wherein the mixed monovalent salt of dimyristoylphosphatidyl contains not more than about 0.05% by weight of the mixed salt of calcium.


25. The solution according to claim 22 additionally comprising dimyristoylphosphatidyl choline.

26. A liposome comprising a solution according to claim 22.

27. A lipid complex comprising a solution according to claim 22.

28. A solution of a mixed salt of dimyristoylphosphatidyl glycerol which contains from about 2.0 percent to about 2.32 percent by weight ammonium.

1/1

FIG. 1

SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US91/02608

I. CLASSIFICATION OF SUBJECT MATTER (In several classification symbols apply, indicate all *) According to International Patent Classification (IPC) or to both National Classification and IPC IPC(5): C12P 13/00, 9/00; C07C 229/00 U.S.Cl.: 435/128, 131; 558/170																				
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched ¹</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 20%; border: 1px solid black; text-align: left;">Classification System</th> <th style="border: 1px solid black; text-align: left;">Classification Symbols</th> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top;">U.S.</td> <td style="border: 1px solid black; vertical-align: top;">435/128, 131; 558/170, 169, 166, 70; 260/403</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ²</div> <p style="margin-top: 10px;">APS, BIOSIS</p>			Classification System	Classification Symbols	U.S.	435/128, 131; 558/170, 169, 166, 70; 260/403														
Classification System	Classification Symbols																			
U.S.	435/128, 131; 558/170, 169, 166, 70; 260/403																			
III. DOCUMENTS CONSIDERED TO BE RELEVANT ³ <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border: 1px solid black; text-align: left;">Category ⁴</th> <th style="width: 60%; border: 1px solid black; text-align: left;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 30%; border: 1px solid black; text-align: left;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top;">X Y</td> <td style="border: 1px solid black; vertical-align: top;">US,A, 4,783,402 (Kokusho et al.) 08 November 1988, See entire disclosure.</td> <td style="border: 1px solid black; vertical-align: top;">1-12,15-19, 22-25,28</td> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top;">Y</td> <td style="border: 1px solid black; vertical-align: top;">US,A, 3,652,397 (Pardun) 28 March 1972, See entire disclosure.</td> <td style="border: 1px solid black; vertical-align: top;">1-12,15-19, 22-25,28</td> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top;">X,P</td> <td style="border: 1px solid black; vertical-align: top;">US,A, 4,997,761 (Jett-Tilton) 05 March 1991, See entire disclosure.</td> <td style="border: 1px solid black; vertical-align: top;">13-14,20-21, 26-27</td> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top;">X</td> <td style="border: 1px solid black; vertical-align: top;">US,A, 4,587,055 (Regen) 06 May 1986, See entire disclosure.</td> <td style="border: 1px solid black; vertical-align: top;">13-14,20-21, 26-27</td> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top;">X</td> <td style="border: 1px solid black; vertical-align: top;">US,A, 4,235,792 (Hsia et al.) 25 November 1980, See entire disclosure.</td> <td style="border: 1px solid black; vertical-align: top;">13-14,20-21, 26-27</td> </tr> </table>			Category ⁴	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X Y	US,A, 4,783,402 (Kokusho et al.) 08 November 1988, See entire disclosure.	1-12,15-19, 22-25,28	Y	US,A, 3,652,397 (Pardun) 28 March 1972, See entire disclosure.	1-12,15-19, 22-25,28	X,P	US,A, 4,997,761 (Jett-Tilton) 05 March 1991, See entire disclosure.	13-14,20-21, 26-27	X	US,A, 4,587,055 (Regen) 06 May 1986, See entire disclosure.	13-14,20-21, 26-27	X	US,A, 4,235,792 (Hsia et al.) 25 November 1980, See entire disclosure.	13-14,20-21, 26-27
Category ⁴	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³																		
X Y	US,A, 4,783,402 (Kokusho et al.) 08 November 1988, See entire disclosure.	1-12,15-19, 22-25,28																		
Y	US,A, 3,652,397 (Pardun) 28 March 1972, See entire disclosure.	1-12,15-19, 22-25,28																		
X,P	US,A, 4,997,761 (Jett-Tilton) 05 March 1991, See entire disclosure.	13-14,20-21, 26-27																		
X	US,A, 4,587,055 (Regen) 06 May 1986, See entire disclosure.	13-14,20-21, 26-27																		
X	US,A, 4,235,792 (Hsia et al.) 25 November 1980, See entire disclosure.	13-14,20-21, 26-27																		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>⁴ Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>																				
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; border-bottom: 1px solid black;">Date of Mailing of the International Search Report</td> </tr> <tr> <td style="border-bottom: 1px solid black; text-align: center;">16 July 1991</td> <td style="border-bottom: 1px solid black; text-align: center;">30 JUL 1991</td> </tr> <tr> <td style="border-bottom: 1px solid black;">International Searching Authority</td> <td style="border-bottom: 1px solid black; text-align: center;"> <div style="text-align: center;"> Susan M. Weber </div> </td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of the International Search Report	16 July 1991	30 JUL 1991	International Searching Authority	<div style="text-align: center;"> Susan M. Weber </div>												
Date of the Actual Completion of the International Search	Date of Mailing of the International Search Report																			
16 July 1991	30 JUL 1991																			
International Searching Authority	<div style="text-align: center;"> Susan M. Weber </div>																			
ISA/US																				

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	US,A, 4,485,045 (Regen) 27 November 1984, See entire disclosure.	1-28
X	Applied Microbiology and Biotechnology, Volume 27, issued 1987, Juneja et al, "Repeated batch and continuous operations for phosphatidyl glycerol synthesis from phosphatidylcholine with immobilized phospholipase D", pages 146-151, See entire disclosure.	1-12,15-19, 22-25,28
X	Enzyme and Microbial Technology, Volume 9, Number 6, issued 1987, Juneja et al, "Comparative study on conversion of phosphatidylcholine to phosphatidyl-glycerol by cabbage phospholipase D in micelle and emulsion systems", pages 350-354, See entire disclosure.	1-12,15-19, 22-25,28
X, P	EP,A, 0,399,544 (Nishide et al) 28 November 1990, See entire disclosure.	1-12,15-19, 22-25,28
X	WO,A, 89/01524 (Redemann) 23 February 1989, See entire disclosure.	1-12,15-19, 22-25,28
X	JP,A, 62-205,788 (Shimizu et al) 10 September 1987, See entire disclosure.	1-12,15-19, 22-25,28
X	SU,A, 831,129 (Kostetsky et al) 23 May 1981, See entire disclosure.	1-12,15-19, 22-25,28

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers _____, because they relate to subject matter ¹² not required to be searched by this Authority, namely:

2. ☐ Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out ¹³, specifically:

3. ☐ Claim numbers _____, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING¹

This International Searching Authority found multiple inventions in this international application as follows:

See attachment.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application. **Telephone practice**
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all search fee exceptions could be claimed without a third payment of an additional fee, the International Searching Authority shall not make payment of any additional fee.

Remarks on Priority:

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ For protest accompanied the international search fees.

Attachment to PCT Telephone Memorandum

I. Claims 1-13, drawn to a process for forming a soluble monovalent salt of a phosphatidyl ester and a liposome formed from such salt, classified in Class 435, subclass 128.

II. Claim 14, drawn to a lipid complex comprising a phosphatidyl ester, classified in Class 558, subclass 170.

III. Claims 15-19, drawn to a process for forming a soluble mixed ammonium/sodium salt of dimyristoylphosphatidyl glycerol, classified in Class 435, subclass 128.

IV. Claim 20, drawn to a liposome comprising dimyristoylphosphatidyl glycerol, classified in Class 558, subclass 170.

V. Claim 21, drawn to a lipid complex comprising dimyristoylphosphatidyl glycerol, classified in Class 558, subclass 170.

VI. Claims 22-25, drawn to an aqueous solution of mixed salt, classified in Class 435, subclass 128.

VII. Claim 26, drawn to a liposome comprising a solution, classified in Class 558, subclass 170.

VIII. Claim 27, drawn to a lipid complex comprising a solution, classified in Class 558, subclass 170.

IX. Claim 28, drawn to a solution of mixed salt, classified in Class 435, subclass 128.

The claims of these nine groups are drawn to distinct inventions which are not linked as to form a single general inventive concept. PCT Rule 13.1 and 13.2 do not provide for multiple products and methods.

ATTACHMENT A (Continuation of Part VI)

VI. Observations Where Unity Of Invention Is Lacking

This International Searching Authority found multiple inventions in this international application as follows:

I. Claims 1-13, drawn to a process for forming a soluble monovalent salt of a phosphatidyl ester and a liposome formed from such salt, classified in Class 435, subclass 128.

II. Claim 14, drawn to a lipid complex comprising a phosphatidyl ester, classified in Class 558, subclass 170.

III. Claims 15-19, drawn to a process for forming a soluble mixed ammonium/sodium salt of dimyristoylphosphatidyl glycerol, classified in Class 435, subclass 128.

IV. Claim 20, drawn to a liposome comprising dimyristoylphosphatidyl glycerol, classified in Class 558, subclass 170.

V. Claim 21, drawn to a lipid complex comprising dimyristoylphosphatidyl glycerol, classified in Class 558, subclass 170.

VI. Claims 22-25, drawn to an aqueous solution of mixed salt, classified in Class 435, subclass 128.

VII. Claim 26, drawn to a liposome comprising a solution, classified in Class 558, subclass 170.

VIII. Claim 27, drawn to a lipid complex comprising a solution, classified in Class 558, subclass 170.

IX. Claim 28, drawn to a solution of mixed salt, classified in Class 435, subclass 128.